Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GMTXNASDAQ:NERVNASDAQ:SPPINASDAQ:SPRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMTXGemini Therapeutics$52.96-2.8%$48.46$1.16▼$14.10$2.29B-0.12189,291 shs313,031 shsNERVMinerva Neurosciences$1.72-0.1%$1.68$1.15▼$3.50$11.95M-0.3722,809 shs8,676 shsSPPISpectrum Pharmaceuticals$1.03$1.01$0.32▼$1.57$211.41M2.151.93 million shsN/ASPROSpero Therapeutics$2.91+0.2%$1.67$0.51▼$3.09$162.31M1.281.19 million shs369,417 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMTXGemini Therapeutics0.00%+5.60%+16.75%+9.79%+20.92%NERVMinerva Neurosciences-3.37%-2.82%+11.25%+10.97%-46.08%SPPISpectrum Pharmaceuticals0.00%0.00%0.00%0.00%0.00%SPROSpero Therapeutics-1.36%-1.02%+12.40%+317.87%+123.08%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGMTXGemini TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANERVMinerva Neurosciences4.1461 of 5 stars3.04.00.04.62.20.01.3SPPISpectrum Pharmaceuticals0.4925 of 5 stars0.00.00.04.70.60.00.6SPROSpero Therapeutics4.2835 of 5 stars3.35.00.04.72.50.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGMTXGemini Therapeutics 0.00N/AN/AN/ANERVMinerva Neurosciences 2.00Hold$5.00190.87% UpsideSPPISpectrum Pharmaceuticals 0.00N/AN/AN/ASPROSpero Therapeutics 2.50Moderate Buy$5.0072.12% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGMTXGemini TherapeuticsN/AN/AN/AN/A$2.89 per shareN/ANERVMinerva NeurosciencesN/AN/A$0.20 per share8.52($3.67) per shareN/ASPPISpectrum Pharmaceuticals$10.11M20.91N/AN/A$0.15 per share6.87SPROSpero Therapeutics$47.98M3.39N/AN/A$0.85 per share3.42Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGMTXGemini Therapeutics-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/ANERVMinerva Neurosciences$1.44M$0.822.09N/AN/AN/A-20.68%15.73%8/5/2025 (Estimated)SPPISpectrum Pharmaceuticals-$75.40M-$0.36N/A14.71N/AN/A-218.44%-66.16%N/ASPROSpero Therapeutics-$68.57M-$1.28N/AN/AN/A-156.48%-123.50%-58.96%8/4/2025 (Estimated)Latest NERV, GMTX, SPRO, and SPPI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025NERVMinerva Neurosciences-$1.07-$0.50+$0.57-$0.50N/AN/A5/13/2025Q1 2025SPROSpero Therapeutics-$0.55-$0.25+$0.30-$0.25$11.00 million$5.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGMTXGemini TherapeuticsN/AN/AN/AN/AN/ANERVMinerva NeurosciencesN/AN/AN/AN/AN/ASPPISpectrum PharmaceuticalsN/AN/AN/AN/AN/ASPROSpero TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGMTXGemini TherapeuticsN/A71.4971.49NERVMinerva NeurosciencesN/A9.219.21SPPISpectrum PharmaceuticalsN/A2.712.38SPROSpero TherapeuticsN/A2.562.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGMTXGemini Therapeutics75.42%NERVMinerva Neurosciences34.56%SPPISpectrum Pharmaceuticals21.67%SPROSpero Therapeutics25.60%Insider OwnershipCompanyInsider OwnershipGMTXGemini Therapeutics12.90%NERVMinerva Neurosciences8.60%SPPISpectrum Pharmaceuticals2.70%SPROSpero Therapeutics5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGMTXGemini Therapeutics3043.33 million37.74 millionNot OptionableNERVMinerva Neurosciences96.99 million6.39 millionNot OptionableSPPISpectrum Pharmaceuticals86205.25 million199.70 millionOptionableSPROSpero Therapeutics15055.91 million52.84 millionOptionableNERV, GMTX, SPRO, and SPPI HeadlinesRecent News About These CompaniesSpero Therapeutics (NASDAQ:SPRO) Stock Passes Above Fifty Day Moving Average - What's Next?July 1 at 3:38 AM | marketbeat.comWhile institutions own 20% of Spero Therapeutics, Inc. (NASDAQ:SPRO), retail investors are its largest shareholders with 54% ownershipJune 28 at 10:04 AM | finance.yahoo.comSpero Therapeutics, Inc. (SPRO) Cash Flow - Yahoo FinanceJune 26, 2025 | finance.yahoo.comSpero Therapeutics (NASDAQ:SPRO) Upgraded to "Hold" at Wall Street ZenJune 21, 2025 | marketbeat.comSpero Therapeutics (NASDAQ:SPRO) Shares Pass Above 200 Day Moving Average - What's Next?June 19, 2025 | marketbeat.comSpero Therapeutics, Inc. (NASDAQ:SPRO) Short Interest Up 446.6% in MayJune 11, 2025 | marketbeat.comSpero Therapeutics -- Additional Upside Potential Following Positive Phase 3 ResultsJune 11, 2025 | seekingalpha.comSpero Therapeutics, Inc. (NASDAQ:SPRO) Stake Boosted by Mackenzie Financial CorpJune 6, 2025 | marketbeat.comWhy Spero Therapeutics, Inc. (SPRO) Surged Last WeekMay 31, 2025 | msn.comWhy Spero Therapeutics, Inc. (SPRO) Surged Last WeekMay 31, 2025 | insidermonkey.comGSK & Spero Therapeutics announce PIVOT-PO phase III study for tebipenem HBr stopped early for efficacy following review by IDMCMay 30, 2025 | pharmabiz.comPSpero Therapeutics rockets on positive Phase III study for tebipenem HBrMay 29, 2025 | thepharmaletter.comTSpero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 MilestoneMay 29, 2025 | msn.comSPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study GoalMay 29, 2025 | zacks.comGSK, Spero report Phase 3 win for UTI antibiotic; Spero's stock soarsMay 28, 2025 | endpts.comEGSK's $66M bet on Spero's rejected UTI antibiotic pays off with a phase 3 winMay 28, 2025 | fiercebiotech.comFSpero Therapeutics Shares Soar as Trial with GSK Ends Early on EfficacyMay 28, 2025 | marketwatch.comSpero Therapeutics Stock Skyrockets on Strong Phase 3 Trial ResultsMay 28, 2025 | msn.comSpero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring CommitteeMay 28, 2025 | globenewswire.comSpero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue EstimatesMay 13, 2025 | zacks.comSpero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business UpdateMay 13, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeRussell Rebalance: 3 Stocks Ready to Move HigherBy Chris Markoch | June 20, 2025View Russell Rebalance: 3 Stocks Ready to Move HigherNERV, GMTX, SPRO, and SPPI Company DescriptionsGemini Therapeutics NASDAQ:GMTX$52.96 -1.54 (-2.83%) As of 06/30/2025Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.Minerva Neurosciences NASDAQ:NERV$1.72 0.00 (-0.06%) As of 03:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.Spectrum Pharmaceuticals NASDAQ:SPPISpectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.Spero Therapeutics NASDAQ:SPRO$2.90 +0.01 (+0.17%) As of 03:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
